Nxera Pharma Full Year 2024 Earnings: Misses Expectations

Nxera Pharma (TSE:4565) Full Year 2024 Results

Key Financial Results

• Revenue: JP¥28.8b (up 126% from FY 2023).
• Net loss: JP¥4.84b (loss narrowed by 33% from FY 2023).
• JP¥53.92 loss per share (improved from JP¥87.17 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nxera Pharma Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 168%.

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Nxera Pharma's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.